1. Henshaw SK: Unintended Pregnancy in the United States. Family Planning Prospective, 1998, vol. 30, p 24-29.

2. Jones RK, Darroch JE, Henshaw SK. Contraceptive use among US women having abortions in 2000-2001. Perspect Sex Reprod Health 2002; 34:294-303.

3. Alan Guttmacker Institute: Sharing Responsibility: Women, Society, and Abortion Worldwide. New York, NY, Alan Guttmacker Institute, 1999.

4. Alan Guttmacker Institute: Sex and America's Teenagers. New York, NY, Alan Guttmacker Institute, 1994: p46.

5. Schwingl PJ, Ory HW, Visness CW: Estimates of the Risk of Cardiovascular Death Attributable to Low Dose Oral Contraceptives in the United States. Am J Obstet Gynecol, 1999, vol 1.

6. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003;68:89-96.

7. Contraceptive Technology. Robert A. Hatcher (ed). 17th Revised Edition, 1998. Ardent Media Incorporated, p 410.

8. Kaunitz AM. Noncontraceptive health benefits of oral contraceptives. Rev Endocrin Metab Disorders. 2002;3:277-283.

9. Schlesselman JJ. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstet Gynecol 1995;85:793-801.

10. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral contraceptive use. N Engl J Med 1987;316:650-5.

11. Ness RB, Grisso JA, Cottreau C, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000;11:111-7.

12. Prentice RL, Thomas DB. On the epidemiology of oral contraceptives and disease. Adv Cancer Res 1987;49:285-401.

13. Schlesselman JJ. Oral contraceptives and neoplasia of the uterine corpus. Contraception 1991;43:557-79.

14. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer. JAMA 1987;257:796-800.

15. Mishell DR Jr. Noncontraceptive benefits of oral contraceptives. J Reprod Med 1993;38:1021-9.

16. Peterson HB, Lee NC. The health effects of oral contraceptives: misperceptions, controversies, and continuing good news. Clin Obstet Gynecol 1989;32:339-55.

17. Ory HW. The noncontraceptive health benefits from oral contraceptive use. Fam Plan Perspect 1982;14:182-4.

18. Brinton LA, Vessey MP, Flavel R, et al. Risk factors for benign breast disease. Am J Epidemiol 1981;113:203-14

19. Mishell DR Jr. Noncontraceptive benefits of oral contraceptives. Am J Obstet Gynecol 1982;142:809-16

20. Kleerekoper M, Brienza RS, Schultz LR, et al. Oral contraceptive use may protect against low bone mass. Arch Intern Med 1991;151:1971-6.

21. Michaelsson K, Baron JA, Farahmand BY, et al. Oral contraceptive use and risk of hip fracture: a case-control study. Lancet 1999;353:1481-4.

22. Hall ML, Heavens J, Cullum ID, Ell PJ. The range of bone density in normal British women. Br J Radiol 1990;63:266-9.

23. Mazess RB, Barden HS. Bone density in premenopausal women: effects of age, dietary intake, physical activity, smoking and birth control pills. Am J Clin Nutr 1991;53:132-42.

24. DeCherney A. Bone-sparing properties of oral contraceptives. Am J Obstet Gynecol 1996;174:15-20.

25. Lanes SF, Birmann B, Walker AM, Singer S. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol 1992;166:956-61.

26. Holt VL, Daling JR, McKnight B, et al. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. Obstet Gynecol 1992;79:529-33.

27. Fernandez E, La Vecchia C, Balducci A, et al. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cacner 2001;84:722-7.

28. Martinez ME, Grodstein F, Giovannucci E, et al. A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. Cancer Epidemiol Biomark Prev 1997;6:1-5.

29. Davis A, Lippman J, Godwin A, et al. Triphasic norgestimate/ethinyl estradiol oral contraceptive for the treatment of dysfunctional bleeding. Obstet Gynecol 2000;95:S84.

30. van Hooff MH, Hirasing RA, Kaptein MB, et al. The use of oral contraceptives by adolescents for contraception, menstrual problems, or acne. Acta Obstet Gynecol Scand 1998;77:898-904.

31. Redmond GP, Olson WH, Lippman JS, et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997;89:615-22.

32. Lucky AW, Henderson TA, Olsen WH, et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol m1997;37:746-54.

33. Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acen treatment. Cutis 2004; 74: 123-30

34. Haider A, Shaw JC. Treatment of Acne Vulgaris. JAMA 2004; 292:726-735

35. Thiboutot D, Archer DF, Lemay A, et al. A randomized controlled trial of a low dose contraceptive containing 20microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. Fertil Steril 2001; 76:461-468

36. Victory R, D'Souza C, Diamond MP, McNeeley SG, Vista Dect D, Hendrix, S. Adverse cardiovascular disease outcomes are reduced in women with history of oral contraceptive use: results from the Women's Health Initiative Database. Fert Steril 2004;82(2):52-53

37. Victory R, D'Souza C, Diamond MP, McNeeley SG, Vista Dect D, Hendrix, S. Reduced cancer risks in oral contraceptive users: Results from the Women's Health Initiative. Fert Steril 2004; 28(2): 104-5

38. Marchbanks PA, McDonald JA, Wilson JG, Folger SG, Mandel MG, Daling JR et al. Oral contraceptives and the risk of breast cancer. N Eng J Med 2002;346:2025-2032.

39. ACOG practice bulletin. The use of hormonal contraception in women with co-existing medical conditions. Number 18, 2000, In J Gynaecol OBstet 2001;75:93-106.

40. Inman WHM, Vessey MP, Westerholm B, et al: Thromboembolic Disease and the Steroidal Component of Oral Contraceptions - A Report of the Committee on Safety of Drugs. Brit Med J 2:203-209, 1970.

41. Michel D: Oral Contraceptives and Cardiovascular Events: Summary and Application of Data. Inter J Fertil, 45(suppl 2):121-133,2000.

42. Jick H, Jick SS, Gurewich V, Myers MW, Dasilakis C: Risk of Idiopathic Cardiovascular Disease and of Non-fatal Venous Thromboembolism in Women Using Oral Contraceptives with Differing Progestagen Components. Lancet 346:1589-1593, 1995.

43. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, McCrae KT: Third Generation Oral Contraceptives and Risk of Venous Thromboembolic Disorders: An International Case Study. Brit Med J 312:83-88, 1996.

44. WHO. Collaborative Study of Cardiovascular Diseases and Steroid Hormone Contraception. Venous Thromboembolic Disease and Combined Oral Contraceptives: Results of International Multicentre Case-Controlled Study. Lancet 346:1575-1582, 1995.

45. Farmer RDT, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR: Population-based Study of Risk of Venous Thromboembolism Associated with Various Oral Contraceptives. Lancet 349:83-88, 1997.

46. Hennessey S, Berlin JA, Kinman JL, Margolis DJ, Marcus SM, Strom BL. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception 2001;62(2):125-33.

47. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001;323:1-9.

48. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002;65(3):187-96.

49. Vandenbrouke JP, Koster T, Breit E, Reitsma PH, Bertina RM, Rosendaal FR: Increased Risk of Venous Thrombosis in Oral Contraceptive Users Who are Carriers of Factor V Leiden Mutation. Lancet 344:1453-1457, 1994.

50. Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999;81(2):198-202.

51. Girolami A, Tormene D, Simioni P, Zanon E. Long-tern use of oral contraceptive therapy in women with prothrombin 20210G-A polymorphism without thrombotic complications: a study of 13 women (12 heterozygotes and 1 homozygote). Thrombosis Res 2001;102:205-10.

52. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000;160(1):49-52.

53. Emmerich J, Rosendaal FR, Cataneo M, Margaglione M, De Stefano V, Cumming T, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001;86(3):809-16.

54. WHO Scientific Group on Cardiovascular Disease and Steroid Hormone Contraception: Cardiovascular Disease and Steroid Hormone Contraception: Report of the WHO Scientific Group. WHO Technical Report 877. Geneva, Switzerland, 1998.

55. WHO Collaborative Study on Cardiovascular Disease and Steroid Hormone: Ischemic Stroke and Combined Oral Contraceptive: Results of an International Multicenter Case-Controlled Study. Lancet 348:498-509, 1996.

56. World Health Organization. Medical Eligibility Criteria for Contraceptive Use, 3rd ed. Geneva; 2003

57. Speroff L. Oral Contraceptive and Breast Cancer Risk: Summary and Application of Data. Inter J Fertil, 45(suppl 2):113-120, 2000.

58. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346:2025-32.

59. Collaborative Group on Hormonal Factors in Breast Cancer: Breast Cancer and Hormonal Contraceptives: Collaborative Reanalysis of Individual Data on 53,297 Women with and 100,239 Women without Breast Cancer from 54 Epidemiologic Studies. Lancet 347:1713-1727, 1996.

60. Oral Contraceptive and Liver Cancer. The Contraceptive Report Nov. 1997, vol. 8, #5.

61. Westoff C, Kerns J, MOrroni C, Cushman LF, Tiezzi L, Murphy PA. Quick Start: A novel oral contraceptive initiation method. Contraception 2002; 66:141-145.

62. Krattenmacher, R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38.

63. An open-label, multi-center, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive. The Mircette Study Group. Am J Obstet Gynecol 1998;179(1);S2-8.

64. Genazzani AR, Stomati M, Morittu A, et al. Progesterone, progestogens and the central nervous system. Hum Reprod 2000;15(suppl 1):S14-S27

65. Arafat S, Hargrove J, Maxon W, et al. Sedative and hypnotic effects of oral administration of micronized progesterone may be mediated through its metabolites. Am J Obstet Gynecol 1988;159:1203-9.

66. Zwain IH, Yen SS. Neurosteroidogenesis in astrocytes, oligodendrocytes and neurons of cerebral cortex of rat brain. Endocrinology 1999;140:3843-52.

67. Backstrom T, Lindhe BA, Cavalli-Bjorkman B, et al. Effects of oral contraceptives on mode: a randomized comparison of threephasic and monophasic preparations. Contraception 1992;46:253-68.

68. Kaunitz AM, Garceau RJ, Cromie MA, et al: Comparative Safety, Efficacy, and Cycle Control of Lunelle Monthly Contraceptive Injection and OrthoNovum 7/7/7 Oral Contraceptive. Contraception 1999: 60; 179-187.

69. Hall PE: The introduction of Cyclofem in National Family Planning Programs Experiences from Studies in Indonesia, Jamaica, Mexico, Thailand, and Tunisia. J Contraception, 1994: 49; 489-507.

70. Cautinho EM, Souza JC: Contraception Control by Monthly Injections of Medroxyprogesterone Suspension and Long-acting Estrogen. J Repro Fert 1968: 15; 209-214.

71. Schulman LP, Oleen-Burkey M, Willke RJ: Patient Acceptability and Satisfaction with Lunelle Monthly Contraceptive Injection. Contraception 1999: 60; 215-222.

72. Bahamonds L, Lavin P, Oheba G, et al: Return to Fertility after Discontinuation of the Once a Month Injectable Contraceptive, Cyclofem. Contraception 1997: 55; 307-310.

73. Rahimy MH, Ryan KK, Hopkins NK: The Lunelle Monthly Contraceptive Injection: Steady State Pharmokinetics of MPA and E2 in Surgically Sterile Women. Contraception 1999: 60; 209-214.

74. Creasy GW, Abrams LS, Fisher AC. Transdermal Contraception. Semin Reprod Med 2001;19(4):373-80.

75. Smallwood GH, Meador ML, Lenihan JP, et al. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2001;98:799-805.

76. Archer DF, Bigrigg, Smallwood GH. Assessment of compliance with a contraceptive patch (Ortho Evra TM/Evra TM) among North American women. Fertil Steril 2002;77:S27-S31

77. Murthy AS, Creinin MD, Harwood BJ, Schreiber CA. Same day initiation of the transdermal hormonal delivery system (contraceptive patch) versus traditional initiation methods. Contraception 2005;72:333-6

78. Macht DI.The absorption of drugs and poisons through the vagina. J Pharmacol 10:509.

79. Barnhart K, Shalaby W: The Vagina: Physiologic Characteristics Important to Formulators of Microbicides. In: Rencher (ed): Vaginal Microbicide Formulations Workshop. Lippincott-Raven Publishers, 1998.

80. Timmer CJ, Mulders TMT. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000; 39:233-242.

81. Mulders TMT, Dieben, TOM. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril 2001; 75:865-870.

82. Roumen FJME, Apter D, Mulders TMT, et al. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethiny oestradiol. Human Reprod 2001; 16:469-475.

83. Landgren BM, Diczfalusy E. Hormonal effects of the 300mcg norethisterone (NET. minipill, 1. Daily steroid levels in 43 subjects during a pretreatment cycle and during the second month of NET administration. Contraception 1980;21:87-113.

84. Oberti C, Dabancens A, Garcia-Huidobro M, et al. Low dosage oral progestogens to control fertility. II. Morphologic modifications in the gonad and oviduct. Obstet Gynecol 1974;43:285-94.

85. Kim-Bjorklund T, Lundgren BM, Johannisson E. Morphometric studies of the endometrium, the fallopian tube and the corpus luteum during contraception with the 300mcg norethisterone (NET. minipill. Contraception 1991;43:459-74.

86. Martinez-Manautou J, Giner-Velasquez J, Cortes-Gallegos V, et al. Daily progestogen for contraception: a clinical study. Br Med J 1967;2:730-2.

87. Barnhart KT, Devoto L, Pommer R, Sir-Pettermann T, Robinovic J, Segal S. Neuroendocrine Mechanism of Anovulation in Users of Contraceptive Subdermal Implant of Nomgestrol Acetate (Uniplant). Fertil Steril 1997;67:250-5.

88. McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994;50(Suppl 1):S9-S195.

89. Fu H, Darroch JE, Haas T, et al. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31:58-63.

90. WHO Task Force on Oral Contraceptives. A randomized, double-blind study of two combined and two progestogen-only oral contraceptives. Contraception 1982;25:243-52.

91. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives: results of an international, multicenter, case-control study. Contraception 1998;57:315-24.

92. Mishell DR Jr. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med. 1996;41(suppl 5):381-90.

93. Cullins VE. Noncontraceptive benefits and therapeutic uses of depot-medroxyprogesterone acetate. J Reprod Med. 1996;41(suppl 5):428-33.

94. Trussell J, Kost K. Contraceptive failure in the United States: A critical review of the literature. Stud Fam Plann. 1987;18:237-83.

95. Kaunitz AM. Long-acting contraceptive options. Int J Fert. 1996;41:69-76.

96. Sangi-Haghpeykar H, Poindexter AN III, Bateman L, et al. Experiences of injectable contraceptive users in an urban setting. Obstet Gynecol. 1996;88:227-33.

97. Mainwaring R, Hales HA, Stevenson K, et al. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. Contraception. 1995;51:149-53.

98. World Health Organization Task Force on Long-Acting Agents for Fertility Regulation. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. Hum Reprod. 1996;11(suppl 2):1-13.

99. Harel Z, Biro FM, Kollar LM. Depo-Provera in adolescents: effects of early second injection or prior oral contraception. J Adolesc Health. 1995;16:379-84.

100. Kaunitz AM. Long-acting hormonal contraception: assessing impact on bone mineral density, weight, and mood. Int J Fert. 1999;44:110-7.

101. Westhoff C, Truman C, Kalmuss D, et al. Depressive symptoms and Depo-Provera. Contraception. 1998;57:237-40.

102. Westhoff C, Wieland D, Tiezzi L. Depression in users of medroxy-progesterone acetate. Contraception. 1995;51:351-4.

103. Westhoff C. Depot Medroxyprogesterone acetate injection (Depo-Provera); a highly effective contraceptive option with proven long term safety. Contraception 2003;68:75-87.

104. Strom BL, Berlin JA, Weber AL, Norman SA, Bernstein L, Burkman RT et al. Absence of an effect of injectable and implantable progestin only contraceptive on subsequent risk of breast cancer. Contraception 2004;69:437-446.

105. Kaunitz A. Current options for injectable contraception in the United States. Seminar in Reproductive Medicine 2001;19:331-336.

106. Westhoff C. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes. J Reprod Med. 1996;41(suppl 5):401-6.

107. Kaunitz AM. Injectable contraception: New and existing options. Obstet Gynecol Clin North Am.2000;27:741-80.

108. Petitti DB, Piaggio G, Mehta S, et al. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. Obstet Gynecol. 2000;95:736-44.

109. Pettiti DB, Piaggio G, Mehta S, Cavioto MC, Meirik O. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population: the WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol. 2000;95:736-744.

110. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology. 2002;13:581-587.

111. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med. 2005;159:139-144.

112. Mishell DR, Jr, Talas M, Parlow AF, et al. Contraception by means of a silastic vaginal ring impregnated with medroxyprogesterone acetate. Am J Obstet Gynecol 1970;107:100-7.

113. Landgren BM, Johannisson E, Masironi B, et al. Pharmacokinetic and pharmacodynamic effects of small doses of norethisterone released from vaginal rings continuously during 90 days. Contraception 1979;19:253-71.

114. Mishell DR Jr, Lumkin M, Jackanicz T. Initial clinical studies of intravaginal rings containing norethindrone and norgestrel. Contraception 1975;12:253-60.

115. Grimes DA, Intrauterine devices and reproductive health: American women in feast and famine. Lancet 2000;356:1013-1019.

116. Croxatto HB, Ortiz ME, Valdez E. IUD mechanism of action. In: Bardin CW, Mishell DR Jr, eds. Proceedings from the Fourth International Conference on IUDs. London:Butterworth-Heinemann, 1994:44-62.

117. WHO Scientific Group. Mechanism of action, safety and efficacy of intrauterine devices. Technical Report Series, No. 753. Geneva: World Health Organization, 1987.

118. Alvarez F, Brache V, Fernandez E, et al. New insights on the mode of action of intrauterine contraceptive devices in women. Fertil Steril 1988;49:768-73.

119. Ortiz ME, Croxatto HB. The mode of action of IUDs. Contraception 1987;36:37-53.

120. Hubacher D, Lara Ricalde R, Taylor DJ, Guerra Infante F, Guzman Rodriguez R. Use of intrauterine device and the risk of infertility among nulligravid women. N Engl J Med 2001;345:561-567.

121. Shelton JD. Risk of clinical pelvic inflammatory disease attributable to an intrauterine device. Lancet 2001;257:443.

122. Chi I-C. Postpartum IUD insertion: timing, route, lactation, and uterine perforation. In: Bardin CW, Mishell DR Jr, eds. Proceedings from the Fourth International Conference on IUDs. London:Butterworth-Heinemann, 1994:219-27.

123. White MK, Ory HW, Rooks JB, et al. Intrauterine device termination rates and the menstrual cycle day of insertion. Obstet Gynecol 1980;55:220-4.

124. Lahteenmaki P, Rauramo I, Backman T. The levonorgestrel intrauterine system in contraception. Steroids 2000;65:693-7.

125. Andersson K, Odlind V, Rybo G. Levornorgestrel-releasing and copper-releasing (Nova T) IUDs during 5 years of use: a randomized comparative trial. Contraception 1994;49:56-72.

126. Hubacher D, Grimes DA. Non contraceptive health benefits of intrauterine devices: A systematic review. Obstet Gynecol Surv 2002;57:120-8

127. Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fert Steril 2003;79:1194-8

128. Fedele L, Bianchi S, Raffaelli R, Portuese A, Dorta M. Treatment of adenomyosis associated menorrhagia with a levonorgestrel releasing intrauterine device. Fert Steril 1997;68:426-9

129. Vercellini P, Frontino G, Giorgi OD, Aimi G, Zaina B, Crosignani PG. Comparison of levonorgestrel releasing intrauterine device versus expectant management after conservative surgery for management of endometriosis: a pilot study. Fert Steril 2002;80:305-9

130. Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivela A et al. Clinical outcomes and costs with levonorgestrel releasing intrauterine system or hysterectomy for treatment of menorrhagia: Randomized trial 5 year follow up. JAMA 2004: 291:1456-1463.

131. Monteiro I, Bahamondes L, Diaz J, Perrotti M, Petta C. Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study (1). Contraception 2002;65(5):325-8.

132. Raudaskoski T, Tapanainen J, Tomas E, Luotola H, Pekonen F, Ronni-Sivula H, et al. Intrauterine 10 microgram and 20 microgram levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 2002;109(2):136-44.

133. Van Look PFA, Stewart F: Emergency Contraception. In Hatcher RA, Trussell J, Stewart F, Katz W, Stewart GK, Guest F, Kowal D: Contraceptive Technology 17th Revised Edition, New York, NY, Ardent Media, 1998.

134. Glasier A: Emergency Postcoital Contraception. NEJM 1997: 337; 1058-1064.

135. Hatcher RA, Trussell J, Stewart F, Holelles S, Russell CR, Kowal D: Emergency Contraception: The Nations Best Kept Secret. Decatur GA: Bridging the Gap Communications, 1995.

136. von Hertzen H, Piaggio G, Ding J, Chen J, Song S, Bartfai G, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002;360:1803-10.

137. Trussell J, Rodriguez G, Ellertson C: New Estimates of the Effectiveness of the Yupze Regime of Emergency Contraception. Contraception 1998: 57; 363-369.

138. Task Force on Post-ovulatory methods of Fertility Regulation. Randomized Control Trial of Levonorgestrel vs the Yupze Regime of Oral Contraceptives for Emergency Contraception. Lancet 1998: 352; 428-433.

139. Piggio G, von Hertzen H, Grimes DA, Van Look PFA: Timing of Emergency Contraception with Levonorgestrel or the Yuspe Regime. Lancet 1999: 353; 721.

140. Swahn ML, Westlund P, Johansson E, Bygdmen M: Effect of Postcoital Contraceptive Methods on the Endometrium and the Menstrual Cycle. Acta Obstet Gynecol Scand 1996: 75; 738-744.

141. Kubb AA, White JO, Guillebud J, Elder MG: The Biochemistry of Human Endometrium after Two Regimes of Postcoital Contraception: A DL-norgestrel/ethinyl estradiol combination or danazol? Fertil Steril 1986: 45; 512-516.

142. Taskin O, Brown RW, Young DC, Poindexter AN, Wiehle RD: High Doses of Oral Contraceptives do not Alter Endometrial a1 and aVβ3 Integrins in the Late Implantation Window. Fertil Steril 1994: 61; 850-855.

143. Raymond EG, Lovely LP, Chen-Mok M, Seppala M, Kurman RJ, Lessey BA: Effects of Yupze Regime of Emergency Contraception on Markers of Endometrial Receptivity. Human Reprod 2000: 15; 2351-2355.

144. Ling WY, Wrixon W, Acorn T, Wilson E, Collins J: Mode of Action of DL-norgestrel and ethinyl estradiol combination in Postcoital Contraception. III Effect of Preovulatory Administration following the Luteinizing Hormone Surge of Ovarian Steroidogenesis. Fertil Steril 1983: 40; 631-636.

145. Raymond EG. Creinin MD. Barnhart KT. Lovvorn AE. Rountree RW. Trussell J. Meclizine for prevention of nausea associated with use of emergency contraceptive pills: a randomized trial. Obstet Gynecol 2000, 95(2):271-7.

146. Raman-Wilms L, Tseng AL, Wighardt S, Einarson TR, Koren G: Fetal Genital Effects of First Trimester Sex Hormone Exposure: A Meta-analysis. Obstet Gynecol 1995: 85; 141-149.

147. Grimes DA. Emergency contraception: Politics trumps science at the US Food and Drug Administration. Obstet Gynecol 2004;104:220-221.

148. Glasier A, Baird D: The Effects of Self-administering contraception. NEJM 1998: 339; 1-4.

149. Kosunen E, Sihvo S, Hemminki E: Knowledge and Use of Hormonal Emergency Contraception in Finland. J Contracept 1997: 55; 153-157.

150. Trussel J, Ellertoson C: Efficacy of Emergency Contraception. Fert Control Rev 1995: 4; 8-11.

151. CDC National Center for Health Statistics. Teenagers in the United States: Sexual Activity, Contraceptive Use, and Childbearing, 2002. Hyattsvile, MD; 2004

152. Ramjee G. Morar NS. Alary M. Mukenge-Tshibaka L. Vuylsteke B. Ettiegne-Traore V. Chandeying V. Karim SA. Van Damme L. COL 1492 study group. Challenges in the conduct of vaginal microbicide effectiveness trials in the developing world. AIDS. 2000;14(16):2553-7.

153. Elias CJ, Leonard A., Family Planning and Sexually Transmitted Diseases: The need to enhance contraceptive choice. Curr Issues Public Health 1995; 1:191-99.

154. Microbicides: Research and Development Status as of March 1999. Products Database prepared by The Alliance for Microbicide Development, Takoma Park Maryland.

155. Kowal D. Coitus Interruptus (Withdrawal). In: Hatcher RA, Trussell J (eds). Contraceptive Technology (17th Revised Edition). New York: Ardent Media, Inc., 1998:303-7.

156. Barnhart KB, Dayal MB. Contraception. In: Rakel RE, Bope ET (eds). Conn's Current Therapy 2002. Philadelphia:W.B.Saunders Company, 2002:1103-11.

157. Labbok M, Cooney K, Coly S. Guidelines: breastfeeding, family planning, and the Lactational Amenorrhea Method - LAM. Washington, D.C.:Institute for Reproductive Health, Georgetown University, 1994.

158. Campbell OMR, Gray RH. Characteristics and determinants of postpartum ovarian function in women in the United States. Curr Opin Obstet Gynecol 1993;169:55-60.

159. Gray RH, Campbell OM, Apelo R, Eslami SS, Zacur H, Ramos RM, Gehret JC, Labbok MH. Risk of ovulation during lactation. Lancet 1990;335:25-9.

160. McNeilly AS. Suckling and the control of gonadotropin secretion. In: Knobil E, Neill JD (eds). The physiology of reproduction (second edition). New York: Raven Press, 1994:1179-212.

161. Lewis PR, Brown JB, Renfree MB, Short RV. The resumption of ovulation and menstruation in a well-nourished population of women breastfeeding for an extended period of time. Fertil Steril 1991;55:529-36.

162. Brunk D. Many men would consider using hormonal methods of contraception: survey highlights experimental methods in gynecology. ObGyn news 2004